Maintaining Competitiveness in Gastrointestinal Endoscopy and Growing the Treatment Device and Surgical Businesses
First written in FY2016. 24 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-07.
4 other companies' latest entry also says "Advanced".
- FY2026WorsenedAnnual report
「In China, ongoing challenges including intensifying competition and measures favoring domestic products weighed on performance in the fourth quarter of the current consolidated accounting period.」
Regarding gastrointestinal endoscopy competitiveness, intensifying competition and measures favoring domestic products in China remained ongoing factors weighing on sales. In addition, shipment suspensions for certain products created headwinds for the therapeutic devices and surgical businesses. - FY2026-H1WorsenedAnnual report
「In gastrointestinal endoscopy, sales increased in Asia and Oceania, including Australia, where performance remained strong. However, sales declined in North America, where customers held back on purchases ahead of the launch of scopes equipped with EDOF (extended depth of field) technology, and in China, where the competitive environment intensified partly because of measures favoring domestic products. In the previous interim consolidated accounting period, sales had benefited from the new-product effect of the EVIS X1 gastrointestinal endoscopy system and the resolution of back orders caused by the Noto Peninsula Earthquake, whereas these effects were absent in the current interim consolidated accounting period, resulting in a year-on-year decline in sales.」
Regarding gastrointestinal endoscopy competitiveness, the company cited customers holding back on purchases in North America ahead of the launch of new scopes and intensifying competition in China due to measures favoring domestic products as factors behind lower sales. - FY2025AdvancedAnnual report
「In gastrointestinal endoscopy, sales declined in China, where the competitive environment has intensified partly because of measures favoring domestic products, while sales increased in North America, where the EVIS X1 gastrointestinal endoscopy system performed well, resulting in year-on-year growth.」
Regarding gastrointestinal endoscopy competitiveness, strong EVIS X1 sales in North America offset lower sales in China, resulting in higher revenue for the field overall. - FY2025AdvancedAnnual report
「Single-use endoscopes: The company launched a bronchoscope in the fiscal year ended March 2022 and a laryngoscope in the fiscal year ended March 2024. It plans to launch a ureteroscope in the fiscal year ending March 2026 and aims to launch single-use endoscopes for the duodenoscope and cholangioscope fields in the future.」
The company has developed a specific plan to expand single-use endoscopes from bronchoscopes and laryngoscopes to ureteroscopes, duodenoscopes and cholangioscopes, including the planned launch of a ureteroscope in the fiscal year ending March 2026. - FY2025-H1AdvancedAnnual report
「In gastrointestinal endoscopy, sales declined in China, which was affected by measures favoring domestic products, while sales increased in North America, where the EVIS X1 gastrointestinal endoscopy system performed well, resulting in year-on-year growth. In surgical endoscopy, sales declined in China but increased in Europe, where products including the VISERA ELITEIII surgical endoscopy system performed steadily. Together with the positive effect of yen depreciation, this resulted in year-on-year growth.」
Sales of EVIS X1 in North America supported gastrointestinal endoscopy, while products including VISERA ELITEIII in Europe supported surgical endoscopy, resulting in year-on-year growth in both fields. - FY2024AdvancedAnnual report
「Single-use endoscopes: The company launched a bronchoscope in the fiscal year ended March 2022 and a laryngoscope in the fiscal year ended March 2024. It plans to launch a ureteroscope in the fiscal year ending March 2025 and aims to launch single-use endoscopes for the duodenoscope and cholangioscope fields in the future.」
In addition to its gastrointestinal endoscopy base, the company has developed a specific plan to expand single-use endoscopes from bronchoscopes and laryngoscopes to ureteroscopes, duodenoscopes and cholangioscopes. - FY2024-Q3AdvancedAnnual report
「By adding Taewoong Medical's medical devices to its product portfolio, the company will provide more comprehensive and diverse solutions in its priority gastroenterology business and help improve patient outcomes.」
Regarding growth in gastrointestinal endoscopy and therapeutic devices, the company acquired Taewoong Medical, which has metal stents for the biliary tract, esophagus, colon and duodenum, expanding its range of solutions for gastroenterology. - FY2024-Q1AdvancedAnnual report
「By product, sales of the EVIS X1 series of gastrointestinal endoscopy systems remained strong, while demand for the previous-generation upper gastrointestinal video scopes and colon video scopes also remained solid, contributing to higher sales. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Regarding gastrointestinal endoscopy competitiveness, strong EVIS X1 series sales and the series’ rising share of sales continued, contributing to higher revenue. - FY2023AdvancedAnnual report
「By product, sales of the EVIS X1 series of gastrointestinal endoscopy systems remained strong, while demand for the previous-generation upper gastrointestinal video scopes and colon video scopes also remained solid, contributing to higher sales. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Strong EVIS X1 series sales and the series’ rising share of sales contributed to higher revenue in gastrointestinal endoscopy. - FY2023-Q3AdvancedAnnual report
「By product, sales of the EVIS X1 series of gastrointestinal endoscopy systems remained strong, while demand for the previous-generation upper gastrointestinal video scopes and colon video scopes also remained solid, contributing to higher sales. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Regarding the strengthening of gastrointestinal endoscopy competitiveness, strong EVIS X1 series sales and the series’ rising share of sales contributed to higher revenue. - FY2023-Q2AdvancedAnnual report
「By product, sales of the EVIS X1 series of gastrointestinal endoscopy systems contributed to higher revenue. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Regarding the maintenance of gastrointestinal endoscopy competitiveness, EVIS X1 series sales contributed to higher revenue, and the series’ share of sales also increased. - FY2022AdvancedAnnual report
「By product, sales of the new EVIS X1 series remained firm, while demand for the previous-generation upper gastrointestinal and lower gastrointestinal scopes also remained solid, contributing to higher sales. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Regarding the maintenance of competitiveness in the core endoscopy business, the company stated that higher EVIS X1 series sales and its rising share of sales contributed to higher revenue. - FY2022-Q2AdvancedAnnual report
「By product, sales of the new EVIS X1 series remained firm, while demand for the previous-generation upper gastrointestinal and lower gastrointestinal scopes also remained solid, contributing to higher sales. The EVIS X1 series is also gradually accounting for a larger share of total sales.」
Regarding the strengthening of gastrointestinal endoscopy competitiveness, the company stated that higher EVIS X1 series sales and its rising share of sales contributed to higher revenue. - FY2021AdvancedAnnual report
「In the gastrointestinal endoscopy field, the flagship new endoscopy system EVIS X1 was introduced in Europe and certain Asian markets in April 2020 and in Japan in July. In October 2020, the company also launched ENDO-AID, an AI-enabled endoscopy computer-aided detection platform, in Europe and certain Asian markets.」
The company expanded the launch area for its flagship new product, EVIS X1, to Japan and launched the AI-enabled ENDO-AID in Europe and certain Asian markets. - FY2021-Q3AdvancedAnnual report
「The flagship new endoscopy system, EVIS X1, was introduced in Europe and certain Asian markets in April 2020 and in Japan in July. However, sales of the endoscopy business declined as promotional activities were constrained by restrictions on visits to customers such as medical institutions and the postponement or cancellation of business meetings due to the COVID-19 pandemic, while the number of procedures fell after professional societies recommended postponing or cancelling gastrointestinal endoscopy examinations.」
The company expanded the launch area for its flagship new product, EVIS X1, to Japan. However, the endoscopy business posted lower sales because promotional activities were constrained by the pandemic and the number of procedures declined. - FY2021-Q2AdvancedAnnual report
「The introduction of these products will further contribute to reducing healthcare costs and improving patients’ quality of life.」
The company acquired Arc Medical Design’s ENDOCUFF product line, expanding its minimally invasive treatment and therapeutic device businesses with devices that assist in the diagnosis and treatment of gastrointestinal diseases. - FY2021-Q1AdvancedAnnual report
「Although the flagship EVIS X1 endoscopy system was launched in Europe and parts of Asia in April 2020, sales in the endoscopy business declined as promotional activities were constrained by restrictions on visits to customers such as medical institutions and the postponement or cancellation of business meetings due to the COVID-19 pandemic. In addition, the number of procedures declined after medical societies recommended postponing or cancelling gastrointestinal endoscopic examinations.」
To maintain and strengthen the competitiveness of gastrointestinal endoscopy, the company introduced its flagship new product, EVIS X1. However, the sales environment was constrained by the pandemic immediately after its launch. - FY2020RaisedAnnual report
「Through ongoing technological innovation and strong sales capabilities, we will further strengthen the competitive advantage of reusable endoscopes, address unmet needs, and expand our product lineup in the single-use endoscope field, which is expected to achieve strong growth overall.」
The company has developed a specific plan to extend its focus on maintaining endoscope competitiveness beyond reusable products to single-use endoscopes, targeting average annual growth of 6% over the next 3 years. - FY2020-Q2AdvancedAnnual report
「The flagship endoscopy system performed steadily in emerging markets, including China. Although developed markets were entering the latter half of the product life cycle, performance in Japan was strong due to front-loaded demand ahead of the consumption tax increase. Sales of the VISERA ELITE Ⅱ surgical endoscopy system also remained steady, increasing revenue from the endoscopy business.」
The core endoscopy systems performed steadily in emerging markets and Japan, while sales of the surgical VISERA ELITE Ⅱ also progressed, offsetting weakness in developed markets where the products were in the latter half of their life cycles. - FY2020-Q1RestatedAnnual report
「The flagship endoscopy system was in the latter half of its product life cycle in developed markets but performed steadily in emerging markets, including China. Sales of the VISERA ELITE Ⅱ surgical endoscopy system also remained steady, increasing revenue from the endoscopy business.」
Flagship endoscopy was in the latter half of its product life cycle in developed markets but remained steady in emerging markets, while VISERA ELITE Ⅱ sales also remained solid. - FY2019-Q3RestatedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product life cycle. In surgery, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales of single-use products used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas were strong.」
Flagship endoscopy remained steady in the latter half of its product life cycle, while strong sales continued in surgery and therapeutic devices. - FY2019-Q2RestatedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product life cycle. In surgery, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales of single-use products used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas were strong.」
Reconfirms that flagship endoscopy remained steady in the latter half of its product life cycle and that product sales were strong in surgery and therapeutic devices. - FY2019-Q1AdvancedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product life cycle. In surgery, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales of disposable products used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas were strong.」
Reports that flagship endoscopy remained steady in the latter half of its product life cycle, alongside progress in sales of new surgical products, THUNDERBEAT and disposable therapeutic devices. - FY2018RestatedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product cycle. In surgery, sales continued to grow for 4K surgical endoscopy systems, 3D endoscopy systems and THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy.」
Reconfirms the strength of flagship endoscopy and growth in 4K and 3D surgical endoscopes and THUNDERBEAT. - FY2018-Q3RestatedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product cycle. In surgery, sales continued to grow for 4K surgical endoscopy systems, 3D endoscopy systems and THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy.」
Reconfirms that flagship endoscopy remained steady even in the latter half of its product cycle and that sales of surgical products continued to grow. - FY2018-Q2RestatedAnnual report
「In gastrointestinal endoscopy, the flagship core endoscopy system performed steadily despite entering the latter half of its product cycle. In surgery, sales continued to grow for 4K surgical endoscopy systems, 3D endoscopy systems and THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy.」
Reconfirms that flagship endoscopy remained steady even in the latter half of its product cycle and that surgical product sales continued to grow. - FY2018-Q1RestatedAnnual report
「In gastrointestinal endoscopy, sales of the flagship core endoscopy system were at the same level as in the same period of the previous year as it entered the latter half of its product cycle. In surgery, 4K surgical endoscopy systems and 3D endoscopy systems performed steadily, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales of disposable guidewires such as VisiGlide 2, used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas, were strong.」
Reconfirms that flagship endoscopy sales were at the same level as in the same period of the previous year, while sales of growth products in surgery and therapeutic devices were strong. - FY2017RestatedAnnual report
「In surgery, 4K surgical endoscopy systems and 3D endoscopy systems performed steadily, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales of disposable guidewires such as VisiGlide 2, used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas, were strong.」
Reconfirms the full-year direction of growing sales of surgical and therapeutic devices while maintaining endoscopy competitiveness. - FY2017-Q3RestatedAnnual report
「In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) both remained strong. In surgery, the integrated endoscopy video system VISERA ELITE (VISERA Elite), which supports endoscopic surgery, and the 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the VisiGlide 2 disposable guidewire, used in endoscopic diagnosis and treatment of the pancreatic and bile ducts.」
Reports similar sales progress in existing areas of competitiveness and growth, including core endoscopy systems, surgical systems, THUNDERBEAT and VisiGlide 2. - FY2017-Q2AdvancedAnnual report
「In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) both remained strong. In surgery, the integrated endoscopy video system VISERA ELITE (VISERA Elite), which supports endoscopic surgery, and the 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the new EZ Shot 3 Plus disposable aspiration biopsy needle (EZ Shot Three Plus), used for endoscopic ultrasound-guided fine-needle aspiration.」
Adds product-level sales progress for areas targeted for competitiveness and growth, including core endoscopy systems, surgical systems, THUNDERBEAT and EZ Shot 3 Plus. - FY2017-Q1AdvancedAnnual report
「In gastrointestinal endoscopy, sales of the flagship EVIS EXERA Ⅲ and EVIS LUCERA ELITE core endoscopy systems were both strong. In surgery, the VISERA ELITE integrated video system supporting endoscopic surgery and 3D endoscopy systems performed steadily, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In therapeutic devices, sales grew for disposable guidewires such as VisiGlide 2, used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas.」
Specifically reports product-level sales progress in existing growth areas, including core endoscopy systems, surgical systems, THUNDERBEAT and VisiGlide 2. - FY2016First statedAnnual report
「The company will pursue substantial growth in therapeutic devices and surgery while maintaining its overwhelming competitiveness in gastrointestinal endoscopy, and improve profitability by strengthening its disposable device business.」
While protecting its existing endoscopy competitiveness, the company is broadening its growth and profitability improvement focus to therapeutic devices, surgery and disposable products.